ClinicalTrials.gov Studies Scraper

ClinicalTrials.gov search: status, phase, conditions, interventions, sponsors, eligibility and sites.

Publisher description, verbatim
Last 7 dayson this actor
Each one reaches followers by email the morning after.Follow this actor
Key figures10 readings
Price / 1k$0.90per 1,000 results
Users / 30d1→ 0 over 10 readings
Users, all time2→ 0 over 10 readings
Runs / 30d9↑ 8 over 9 readings
Runs / user / mo9.00runs per monthly user
Standing
#22of 160

on ClinicalTrials.gov, by users in the last 30 days among actors classified to this platform.

Recorded changes
  • 2026-10-15changeListed—on record
showing 1 of 1 in the last 30 days · followers get the next one by email

History

10 readings since 2026-10-15
Users / 30d10 readings
10-15→ 010-24
Users, all time10 readings
10-15→ 010-24
Runs / 30d9 readings
10-15↑ 810-24
Standing10 readings
10-15↑ 2310-24

Alternatives on ClinicalTrials.gov

The actors either side of #22 of 160, ranked by users in the last 30 days. Same platform, adjacent adoption — the comparable set.

all 160 on ClinicalTrials.gov →
Sort
#ActorGradePrice / 1kUsers /30dSuccessRatingAgeFresh
17—RES$5.00 /1ksteep price23 total——3maging
18—RES$3.00 /1khigh price22 total——3mfresh
19—RES$1.00 /1kgood price11 total——4maging
20—RES$1.00 /1kgood price12 total——6dfresh
21—RES$2.00 /1kfair price12 total——39dfresh
22—RES$0.90 /1kgood price12 total——10dfreshThis
23—EVT$2.00 /1k study-returned12 total——33daging
24—RES$2.00 /1kfair price11 total——4maging
25—RES$9.90 /1ksteep price12 total——23dfresh
26—RES$3.00 /1khigh price12 total——4maging
27—FREEfree12 total——4maging

Follow this actor, compare it against its rivals, and get every overnight change in one morning report.

Publish it yourself? Claim your publisher page and its full history is yours free, forever.

Open in the app Claim this page

Numbers on this page are measured only by an independent census of the Apify Store — not self-reported. Not indexed: too little has happened to this actor for us to have anything worth saying yet.